Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension

Misha Syed, Emma K R Loucks

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the "washout effect" from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives.

Original languageEnglish (US)
Pages (from-to)1291-1296
Number of pages6
JournalClinical Ophthalmology
Volume5
Issue number1
StatePublished - 2011

Fingerprint

Timolol
Ocular Hypertension
Open Angle Glaucoma
Intraocular Pressure
Glaucoma
Therapeutics
Optic Nerve Diseases
Optic Disk
Visual Fields
Compliance
Disease Progression
brinzolamide

Keywords

  • Brinzolamide
  • Fixed combination therapy
  • Glaucoma
  • Ocular hypertension
  • Timolol

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension. / Syed, Misha; Loucks, Emma K R.

In: Clinical Ophthalmology, Vol. 5, No. 1, 2011, p. 1291-1296.

Research output: Contribution to journalArticle

@article{fc079c73135147e68568158d59aaf63b,
title = "Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension",
abstract = "Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1{\%} and timolol maleate 0.5{\%}, which is commercially available in some countries as Azarga{\circledR} for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the {"}washout effect{"} from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives.",
keywords = "Brinzolamide, Fixed combination therapy, Glaucoma, Ocular hypertension, Timolol",
author = "Misha Syed and Loucks, {Emma K R}",
year = "2011",
language = "English (US)",
volume = "5",
pages = "1291--1296",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension

AU - Syed, Misha

AU - Loucks, Emma K R

PY - 2011

Y1 - 2011

N2 - Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the "washout effect" from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives.

AB - Glaucoma encompasses a wide clinical spectrum of disease, with the common pathophysiology of progressive optic neuropathy leading to visual field loss. Elevated intraocular pressure (IOP) is a key risk factor in disease progression. Treatment is aimed at reduction of IOP to minimize continued optic nerve head damage. Pharmacologic treatment with various classes of IOP-lowering medications is generally employed before more aggressive surgical interventions. Monotherapy is generally accepted as initial therapy for glaucoma, but at least half of patients may require more than one IOP-lowering medication. One option is the fixed combination of brinzolamide 1% and timolol maleate 0.5%, which is commercially available in some countries as Azarga® for treatment of glaucoma not adequately responsive to monotherapy. These agents may also be used in an unfixed fashion, but fixed combination therapy is generally more convenient for patients, which may result in improved compliance, a reduction of the "washout effect" from instilling multiple drops, and a potential reduction in the side effects related to multiple doses of preservatives.

KW - Brinzolamide

KW - Fixed combination therapy

KW - Glaucoma

KW - Ocular hypertension

KW - Timolol

UR - http://www.scopus.com/inward/record.url?scp=81055125661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81055125661&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:81055125661

VL - 5

SP - 1291

EP - 1296

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -